ProMIS Neurosciences (PMN) Stock

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential target engagement in patients with Alzheimer's disease

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for year-end 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented positive results from all five cohorts from the Phase 1a, single ascending dose clinical trial of its lead product candidate, PMN310, at the 17th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place from October 29 – November 1, 2024 in Madrid, Spain. PMN310 is an investigational humanized monoclonal antibody (mAb) designed and developed to selectively target soluble amyloid beta oligomers (AβOs), which ProMIS believes to be the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that preclinical data supporting the potential role of its lead product candidate, PMN310, as a treatment for AD will be highlighted in an oral presentation at the 4th International Conference on Cognitive & Behavioral Neurosciences (ICBN) taking place from September 12-13, 2024 in Lisbon, Portugal.

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim Chief Executive Officer of ProMIS Neurosciences and Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 6, 2024 at 12:00 p.m. ET.

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer's disease patients